- Regulatory Status
- RUO
- Other Names
- Insulin-like growth factor binding protein 6 (IBP6), IGFBP6
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Quantity Check Availability | Save | ||
---|---|---|---|---|---|---|
752404 | 25 µg | $347 |
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
Seven IGFBPs has been described to modulate the IGF activity. IGFBPs transport IGFs, in this way they may inhibit mitogenesis, differentiation, survival, and other IGF-stimulated events. IGFBPs structurally are characterized by three domains: the amino-terminal, the carboxyl-terminal, and an intermediate variable L-domain. Members of the IGFBP family exhibit 67–70% structural homology. The greatest homology among the IGFBPs is in the N- and C-terminal regions. Some IGFBPs bind to the extracellular matrix (IGFBP-2, -3, -5, and -6). In fact, a heparin-binding domain (HBD) has been identified in the C-terminal region of these binding proteins. IGFBP-6 decreases cancer cell proliferation and survival by inhibiting the effects of IGF-II. IGFBP-6 has binding preference for IGF-II over IGF-I. In addition to IGF regulation, IGFBP-6 has IGF-independent effects, which include the inhibition of angiogenesis and promotion of rhabdomyosarcoma (RMS) cell migration. Prohibitin-2, a single-span membrane protein, is a key regulator of IGFBP-6-induced RMS cell motility. Recombinant IGFBP-6 can be internalized and translocated to the nucleus, where it interacts with the vitamin D receptor and thyroid hormone receptor alpha 1 (TR). Consequently, IGFBP-6 inhibits osteoblastic differentiation that is mediated by vitamin D3 and regulated by TR in the presence of Triiodothyronine.
Product DetailsProduct Details
- Source
- Mouse IGFBP-6, amino acids (Gly24-Gly238) (Accession# NM_008344), was expressed in 293E cells. The amino-terminal possesses a Met.
- Molecular Mass
- The 216 amino acid recombinant protein has a predicted molecular mass of approximately 22.9 kD. The protein migrates at approximately 30-35 kD in both DTT-reducing and non-reducing conditions by SDS-PAGE. The predicted N-terminal amino acid is Met.
- Purity
- >95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in 0.1% TFA, <30% ACN.
- Endotoxin Level
- Less than 0.01 ng per µg cytokine as determined by the LAL method.
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- ED50 = 0.1 - 0.5 µg/ml as determined by the inhibition of MCF-7 cell proliferation induced by mouse IGF-II (30 ng/ml, Cat. No. 588204).
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Monomer.
- Distribution
-
IGFBP-6 is expressed in ovarian cells, prostatic cells, and fibroblasts. It is found predominantly in cerebral spinal fluid and serum.
- Function
- The protein binds preferentially to IGF-II over IGF-I and regulates their activity. It takes part in osteoblast differentiation, cancer, and angiogenesis. Retinoic acid increases IGFBP-6 expression in human osteoblast cells.
- Interaction
- Osteoblasts, ovarian cancer cells, and rhabdomyosarcoma cells.
- Ligand/Receptor
- IGF-I, IGF-II, vitamin D receptor, and thyroid hormone receptor alpha 1.
- Bioactivity
- Mouse IGFBP-6 inhibits the proliferation of MCF-7 cells induced by mouse IGF-II.
- Cell Type
- Hematopoietic stem and progenitors, Mesenchymal Stem Cells
- Biology Area
- Angiogenesis, Cancer Biomarkers, Cell Biology, Cell Proliferation and Viability, Stem Cells
- Antigen References
-
1. Kelley KM, et al. 1996. Int. J. Biochem. Cell Biol. 28:619.
2. Brewer MT, et al. 1988. Biochem. Biophys. Res. Commun. 152:1289.
3. Murphy LJ, et al. 1998. J. Mol. Endocrinol. 21:97.
4. Ferry RJ, et al. 1999. Horm. Res. 51:53.
5. Cui J, et al. 2011. Mol. Cell Endocrinol. 338:84.
6. Qiu J, et al. 2012. Mol. Cell Biochem. 361:197.
7. Fu P, et al. 2013. J. Biol. Chem. 288:29890.
8. Bach LA, et al. 2013. Clin. Sci. 124:215.
9. Yang Z and Bach LA. 2014. Front Endocrinol. (Lausanne) 5:231. - Gene ID
- 16012 View all products for this Gene ID
- UniProt
- View information about IGFBP-6 on UniProt.org
Related FAQs
- Why choose BioLegend recombinant proteins?
-
• Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
• Greater than 95% Purity or higher, tested on every lot of product.
• 100% Satisfaction Guarantee for quality performance, stability, and consistency.
• Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
• Bulk and customization available. Contact us.
• Learn more about our Recombinant Proteins. - How does the activity of your recombinant proteins compare to competitors?
-
We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
- What is the specific activity or ED50 of my recombinant protein?
-
The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
- Have your recombinants been tested for stability?
-
Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
- Does specific activity of a recombinant protein vary between lots?
-
Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
- How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
-
Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)
Follow Us